




Figure S1



**Number of patients at risk**

<i>Tx not delayed, not discontinued</i>	14	9	7	3	2	0	0	0
<i>Tx delayed, not discontinued</i>	10	8	8	7	3	1	1	0
<i>Tx discontinued</i>	32	6	3	2	0	0	0	0




Log-rank test p=0.006

Days from COVID-19 diagnosis

Number of patients at risk

<i>January-August 2020</i>	127	58	49	38	28	20	14	0
<i>September 2020-February 2021</i>	238	130	95	81	19	0	0	0
<i>March-September 2021</i>	21	8	3	0	0	0	0	0



Figure S3



**Number of patients at risk**

<i>Tx not delayed, not discontinued</i>	11	8	6	4	1	0	0	0
<i>Tx delayed, not discontinued</i>	19	18	14	11	4	2	1	0
<i>Tx discontinued</i>	17	10	6	5	2	2	1	0


Figure S4



Number of patients at risk

	0	100	200	300	400	500	600	700
<i>Tx not delayed, not discontinued</i>	1	1	1	1	0	0	0	0
<i>Tx delayed, not discontinued</i>	7	6	3	2	1	1	1	0
<i>Tx discontinued</i>	14	1	1	1	1	0	0	0

Figure S5



Number of patients at risk

	0	100	200	300	400	500	600	700
<i>Tx not delayed, not discontinued</i>	14	10	5	3	0	0	0	0
<i>Tx delayed, not discontinued</i>	36	32	23	18	6	3	2	0
<i>Tx discontinued</i>	21	10	7	6	3	2	1	0

## **Supplementary figures' legend**

Figure S1. Survival probability by modification of initial chemotherapeutic program due to COVID-19 in 79 with concomitant AML and COVID-19 diagnosis.

Figure S2. Survival probability by observation time (Jan-2020 to Aug-2020 vs Sept-2020 to Feb-2021 vs Mar-2021 to Sept-2021).

Figure S3. Survival probability by modification of initial chemotherapeutic program due to COVID-19 diagnosis in patients receiving consolidation treatment.

Figure S4. Survival probability by modification of initial chemotherapeutic program due to COVID-19 diagnosis in relapsed/refractory patients receiving reinduction treatment.

Figure S5. Survival probability by modification of initial chemotherapeutic program due to COVID-19 diagnosis in CR patients.